Lician Pro · $19.99/mo or $149/yr · AAPL vs MSFT

Ligand Pharmaceuticals Incorporated (LGND) SEC filings

Ligand Pharmaceuticals Incorporated (LGND) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported LGND revenue for 2025-12-31 was $268.1M. Net income was $124.5M. Revenue was up 60.4% from 2024-12-31 to 2025-12-31. LGND currently screens at market cap $2.21B and trailing P/E 125.9. The LGND filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Ligand Pharmaceuticals Incorporated said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.

Earnings & events

All events

earnings callAug 6, 2026

LGND earnings

Event insights for LGND — what management said, what changed, and why it matters.

No cached SEC filings for LGND yet. When an 8-K lands, this page will list it.

These filings as JSON? API free 100/day

LGND SEC filings FAQ

What events are listed on the LGND SEC page?

Cached event headlines on this Ligand Pharmaceuticals Incorporated (LGND) SEC page: "LGND earnings". Events: https://lician.com/sec/lgnd

What is LGND's P/E ratio?

Ligand Pharmaceuticals Incorporated (LGND) trailing P/E is 125.9 on the latest cached fundamentals snapshot.

What are LGND's latest revenue and net income?

Latest cached Ligand Pharmaceuticals Incorporated (LGND) revenue for Dec 31, 2025 was $268.1M. Net income was $124.5M. Statements: https://lician.com/financials/lgnd